Compare PAI & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAI | ICCC |
|---|---|---|
| Founded | 1973 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 93.1M |
| IPO Year | N/A | 1995 |
| Metric | PAI | ICCC |
|---|---|---|
| Price | $11.50 | $10.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 21.9K | 7.4K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $25.34 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $11.24 | $4.52 |
| 52 Week High | $12.95 | $12.10 |
| Indicator | PAI | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 51.34 |
| Support Level | $11.24 | $9.45 |
| Resistance Level | $12.35 | $10.82 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 76.92 | 50.58 |
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. Its primary investment objective is to seek a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. To a lesser extent, the fund also invests in privately placed debt securities and in certain equity securities. Capital appreciation is its secondary investment objective. The fund invests a majority of its net assets in fixed income securities that are rated in the Baa or BBB categories or above at the time of purchase by one or more Nationally Recognized Statistical Rating Organizations (NRSROs) or unrated securities of comparable quality at the time of purchase (as determined by the investment adviser).
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.